StockNews.AI

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

StockNews.AI • 2 days

N/A
High Materiality8/10

Information

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”...

Original source

AI Summary

RenovoRx is experiencing increased adoption of its RenovoCath device by prominent cancer centers, including City of Hope and Moffitt, which may catalyze future revenue growth. The company plans to further its commercialization efforts in 2026, targeting improved oncological treatments and increased market presence. These developments position RenovoRx favorably as it seeks to solidify its market foothold.

Sentiment Rationale

The growing number of active customers and strong institutional adoption signal potential revenue increase, similar to trends observed in other successful medical devices post-commercialization.

Trading Thesis

RNXT is poised for potential upside as adoption increases; target within 12 months.

Market-Moving

  • Increased adoption by major cancer centers could drive RNXT stock performance.
  • Expect revenue boost as RenovoCath ordering expands with ongoing trials.
  • Positive feedback from physicians may enhance investor confidence.
  • Strong commercialization strategy could result in accelerated growth this year.

Key Facts

  • RenovoRx sees growth with more U.S. cancer centers adopting RenovoCath.
  • City of Hope and Moffitt Cancer Center now using RenovoCath for treatment.
  • The company aims to accelerate sales growth through enhanced commercialization strategy.
  • RenovoRx generated $900,000 in revenue through September 2025.
  • Ongoing trials could expand customer base post-enrollment.

Companies Mentioned

  • RenovoRx, Inc. (RNXT): Positive adoption and growth plans could impact stock performance.
  • City of Hope (N/A): Increasing adoption of RenovoCath strengthens clinical validation.
  • Moffitt Cancer Center (N/A): Key player now using RenovoCath, may influence broader cancer center adoption.

Corporate Developments

This news falls under 'Corporate Developments' as it details RenovoRx's commercial momentum with its product. The increasing integration of RenovoCath into significant cancer treatment programs indicates robust corporate growth potential.

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers

MOUNTAIN VIEW, Calif., January 20, 2026 (GLOBE NEWSWIRE) – RenovoRx, Inc. (Nasdaq: RNXT), a leading life sciences company focused on innovative oncology therapies, has announced significant growth in the commercial adoption of its patented RenovoCath drug-delivery device. This expansion includes the integration of RenovoCath into treatment programs at nine cancer centers across the United States, bolstering the Company’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.

Overview of RenovoCath and Its Benefits

The RenovoCath device is designed to deliver chemotherapy directly to tumor sites, potentially enhancing the therapeutic effectiveness while reducing the systemic side effects typically associated with traditional intravenous chemotherapy. This innovative approach represents a major advancement in targeted oncology treatments.

Since September 2025, the number of active cancer centers using RenovoCath has surged from five to nine, with City of Hope Cancer Center in Duarte, California, and Moffitt Cancer Center in Tampa, Florida, among the latest facilities to adopt this technology.

Clinical Insights from Leading Institutions

Dr. Jonathan Kessler, Chief of Interventional Radiology at City of Hope, discussed the transformative potential of RenovoCath in managing challenging tumors, particularly locally advanced pancreatic cancer, in a recent interview on Spectrum News 1 SoCal. To learn more, watch the full interview here.

Additionally, Moffitt Cancer Center shared a detailed account of a pancreatic cancer patient undergoing treatment with the TAMP therapy platform, showcasing the real-world impact of this advanced technology. Read the full newsletter here.

Commercial Strategy and Revenue Growth

Shaun Bagai, CEO of RenovoRx, stated, “The growing adoption of RenovoCath by esteemed institutions like City of Hope and Moffitt Cancer Center is a strong testament to our commercial efforts and the ongoing need for targeted oncology solutions.” In 2025, RenovoRx reported sales revenue of approximately $900,000 through September, demonstrating a promising start as the Company actively commercializes RenovoCath.

Future Outlook

Looking ahead, RenovoRx aims for continued revenue growth in 2026, driven by increasing physician demand and robust training initiatives. The Company has recently built a dedicated commercial team, including a Senior Director of Sales and a Director of Marketing, to enhance its go-to-market strategy.

It is noteworthy that the current count of RenovoCath commercial users does not include centers participating in RenovoRx’s ongoing Phase III TIGeR-PaC trial, which is investigating intra-arterial gemcitabine delivery via RenovoCath for locally advanced pancreatic cancer. These centers could potentially integrate RenovoCath following the trial's completion.

About RenovoRx and RenovoCath

RenovoRx, Inc. (Nasdaq: RNXT) is committed to developing targeted oncology therapies and has successfully commercialized RenovoCath®, an FDA-cleared localized drug-delivery device. The device is designed to enhance the delivery of chemotherapy with the goal of improving patient outcomes and minimizing side effects.

For further information on cancer treatment options utilizing RenovoCath, please visit RenovoCath.com.

Related News